A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae

Curr Microbiol. 2005 Dec;51(6):363-6. doi: 10.1007/s00284-005-0027-9. Epub 2005 Oct 25.

Abstract

A new streptogramin antibiotic XRP 2868 was compared with quinupristin-dalfopristin for inhibitory activities against antibiotic-resistant Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. In each organism examined, XRP 2868 had an IC(50) that was twofold to fivefold lower than quinupristin-dalfopristin, for inhibition of cell viability, protein synthesis, and ribosomal subunit formation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / biosynthesis
  • Drug Combinations
  • Drug Resistance, Bacterial*
  • Haemophilus influenzae / drug effects*
  • Haemophilus influenzae / growth & development
  • Haemophilus influenzae / metabolism
  • Ribosomes / physiology
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / growth & development
  • Staphylococcus aureus / metabolism
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / growth & development
  • Streptococcus pneumoniae / metabolism
  • Streptogramin A / pharmacology*
  • Streptogramin B / pharmacology*
  • Virginiamycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Drug Combinations
  • flopristin, linopristin drug combination
  • Virginiamycin
  • quinupristin-dalfopristin
  • Streptogramin B
  • Streptogramin A